Lenalidomide Market Report, Global, 2024

The lenalidomide market size has grown strongly in recent years. It will grow from $11.05 billion in 2023 to $11.91 billion in 2024 at a compound annual growth rate (CAGR) of 7.8%. During the historical period, the expansion can be credited to FDA approval for multiple myeloma, penetration into new geographic markets, the introduction of generic versions, progressions in clinical research, strategic collaborations, the rising prevalence of blood cancers, and the escalating demand for economically viable treatments.

The lenalidomide market size is expected to see strong growth in the next few years. It will grow to $16.29 billion in 2028 at a compound annual growth rate (CAGR) of 8.2%. The expansion projected for the forecast period can be ascribed to heightened regulatory approvals for extended indications, surging demand for targeted therapies, uptake in emerging markets, increased investments in oncology research and development, a shift in treatment paradigms towards combination therapies, and evolving healthcare policies favoring economical treatment alternatives. Significant trends anticipated in the forecast period encompass heightened adoption in emerging markets, intensified emphasis on combination therapies, growing interest in personalized medicine approaches, regulatory progressions impacting market dynamics, a heightened focus on real-world evidence in treatment determinations, widened applications beyond hematological malignancies, and evolving pricing strategies shaping market competitiveness.

The anticipated rise in blood cancer cases is set to drive the expansion of the lenalidomide market. Blood cancer, characterized by abnormal cells disrupting blood cell production, is influenced by factors such as aging populations, environmental toxins, genetics, and lifestyle changes. Lenalidomide aids in managing blood cancer by modulating the immune system, suppressing cancer cell growth, and facilitating the elimination of malignant cells. For instance, the Cancer Facts and Figures 2023 report from the American Cancer Society revealed an estimated 35,730 new myeloma cases in the US in January 2023, with 19,860 males and 15,870 females. Additionally, around 184,720 individuals in the United States are expected to be diagnosed with leukemia, lymphoma, or myeloma in 2023, further boosting the lenalidomide market growth.

Key players in the lenalidomide market are concentrating on developing innovative drugs, including generic versions of lenalidomide capsules, to cater to the rising demand for cost-effective treatments and broaden their market reach. Generic lenalidomide capsules, reproducing the original drug's effects, are gaining traction. For instance, in February 2022, Sandoz, a Swiss pharmaceutical company, introduced a generic lenalidomide version across 19 European countries. This medication, aligned with the latest ESMO guidelines, provides cost-saving options for patients with multiple myeloma, follicular lymphoma, myelodysplastic syndromes-related anemia, and relapsed or refractory mantle cell lymphoma.

In December 2023, Lotus Pharmaceutical, a US-based biopharmaceutical firm, formed a partnership with Fuji Pharma Co. Ltd. to distribute Lenalidomide capsules, a generic version of Revlimid, in the Japanese market. This collaboration leverages Fuji Pharma's expertise and market presence in producing and selling medical products.

Major companies operating in the lenalidomide market are Bristol-Myers Squibb Company, Novartis AG, Amgen Inc, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd, Aurobindo Pharma, Dr. Reddy's Laboratories, Cipla Limited, Apotex Inc, Zydus Lifesciences Limited, Alvogen, Lotus Pharmaceutical, Natco Pharma Limited, Accord Healthcare, Veranova, Avra Laboratories Pvt. Ltd., Camber Pharmaceuticals Inc., Rochem International Inc, Florencia Healthcare, Alleviare Life Sciences Pvt Ltd., LGM Pharma LLC, Sarv Biolabs Pvt Ltd, Speciality Medicines Private Limited, Healthiza Lifescience Private Limited.

North America was the largest region in the lenalidomide market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lenalidomide market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the lenalidomide market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Lenalidomide, classified as an immunomodulatory drug akin to thalidomide analogs, is chiefly employed in the treatment of multiple myeloma, a form of cancer impacting plasma cells, and in the management of select myelodysplastic syndromes (MDS). It works by modifying the immune system's response and impeding the proliferation and survival of cancerous cells.

Lenalidomide is available primarily in four dosage forms, 5mg, 10mg, 15mg, and 25mg capsules. The 5mg capsules contain 5 milligrams of the active ingredient and are utilized for multiple myeloma (MM), myelodysplastic syndromes (MDS), lymphoma, and other applications within hospitals, cancer treatment centers, and research institutions.

The lenalidomide market research report is one of a series of new reports that provides lenalidomide market statistics, including lenalidomide industry global market size, regional shares, competitors with lenalidomide market share, detailed lenalidomide market segments, market trends, and opportunities, and any further data you may need to thrive in the lenalidomide industry. This lenalidomide market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The lenalidomide market consists of sales of buccal patches, oral tablets, capsules, and powders. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.